Bladerunner, Assuming Org-26576 is a Cortex-developed compound, it's not likely a high impact. As Daviddal said, it may just target areas of the brain believed to be more involved in Depression. Unlike Schizophrenia, which shouldn't require a high impact, Depression should theoretically be better treated with a compound that can upregulate neurotrophins (the neurogenesis angle). Depression is one of the tougher indications for clinical trials, since placebo effects can reportedly be up to 50%.
One thing we may be able to glean from the doses used in the glucose utilization study, is that Org-26576 may be somewhat more potent than Org-24448. It also acts at more areas of the brain.
BTW, Organon does have a compound library of their own, based on their comp of matter patents. Servier also has some compounds of its own too, like S-18986 (a benzothiadiazine). Servier decided to move ahead with that compound instead of using a Cortex compound (Cortex offered CX-717 to Servier years ago, when it was still preclinical), possibly because S-18986 is more neurotrophic than Cortex's low impacts, and perhaps also because Cortex's high impacts aren't yet ready for clinical trials (Servier has been funding Cortex's high impact development program for years, but that research funding agreement ends next month). One would expect S-18986 to have more side effects than a low impact like CX-717, so I was surprised to see Servier dosing S-18986 for 12 months in their current 400 patient MCI Phase 2. After the CX-516 MCI debacle, there was a long multi-year delay before Servier started this S-18986 trial, leading to speculation that S-18986 was in trouble. I guess not, assuming the folks at Servier haven't been drinking too much Merlot again.
